BLAInjectionInjectablePriority Review
Approved
Jun 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
Priority Review
LUCENTIS (ranibizumab) by Roche is vascular endothelial growth factor inhibitors [moa]. Approved for neovascular age-related macular degeneration, macular edema, retinal vein occlusion and 3 more indications. First approved in 2006.
Drug data last refreshed 6d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LUCENTIS (ranibizumab) is a monoclonal antibody fragment that inhibits vascular endothelial growth factor (VEGF), approved in 2006 for wet age-related macular degeneration and other retinal conditions. Administered as an intravitreal injection, it reduces abnormal blood vessel growth and fluid leakage in the eye. The drug represents a foundational anti-VEGF therapy in ophthalmology.
$0.004BPart D
LOE ApproachingDeclining
As LOE approaches, LUCENTIS teams face headcount pressure and resource reallocation toward newer formulations and biosimilar defense strategies.
Mechanism of Action
Vascular Endothelial Growth Factor Inhibitors
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Worked on LUCENTIS at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.